Skip to main content
Arctic Bioscience logo

Arctic Bioscience — Investor Relations & Filings

Ticker · ABS ISIN · NO0010859580 LEI · 549300Z2HW6I989Q2C78 OL Manufacturing
Open in API
Filings indexed 422 across all filing types
Latest filing 2021-03-10 Report Publication Anno…
Country NO Norway
Listing OL ABS

About Arctic Bioscience

https://arctic-bioscience.com/

Arctic Bioscience is a biotechnology company that develops and commercializes pharmaceutical and nutraceutical products derived from marine membrane lipids. The company utilizes proprietary technology to extract bioactive compounds from herring roe, sourced from sustainable, MSC-certified fisheries. Its nutraceutical product line, marketed under the brand name Romega, consists of high-DHA Omega-3 phospholipid extracts. The pharmaceutical division is focused on developing a novel drug candidate for the treatment of mild-to-moderate psoriasis, aligning with its mission to create therapies for autoimmune disorders. The company's work is supported by extensive research and development to validate the efficacy of its marine-based ingredients.

Recent filings

Filing Released Lang Actions
Arctic Bioscience: New company presentation
Report Publication Announcement Classification · 98% confidence The document text explicitly states, "Arctic Bioscience: New company presentation" and further clarifies, "a new company presentation is now available under the investor relations section on the company website and attached to this release." This indicates the document is an announcement about the availability of a presentation, not the presentation itself. Based on the definitions, this aligns best with an Investor Presentation (IP) being announced, but the announcement itself fits the 'Report Publication Announcement' (RPA) category, as it signals the release of another document. Given the very short length (1675 chars) and the focus on announcing availability, RPA is the most appropriate classification according to Rule 2 (The 'MENU VS MEAL' Rule).
2021-03-10 English
Arctic Bioscience AS – Stabilization measures taken
Transaction in Own Shares Classification · 95% confidence The document text consists almost entirely of tabular data showing 'Volume', 'Price (NOK)', 'consideration (NOK)', and 'Date and time (GMT)'. This structure strongly suggests a record of transactions, likely related to share movements. The presence of dates in March 2021 and February 2021 indicates a reporting period, but the content itself is transactional data, not a narrative report or formal financial statement (like 10-K or IR). This type of granular transaction data, especially involving share volumes and prices, is characteristic of insider trading reports (Director's Dealing) or reports on the company's own share transactions (Treasury Stock/Own Shares). Since the data is highly specific transaction logs rather than a general announcement, and given the options, 'Transaction in Own Shares' (POS) or 'Director's Dealing' (DIRS) are the most plausible. Without explicit context stating *who* is trading (insider vs. company), the data format (volume/price/date) is most closely aligned with the detailed reporting required for share transactions. Given the high volume of individual transactions listed, this is likely a report detailing share repurchase/issuance activity, fitting the 'Transaction in Own Shares' (POS) definition best, or potentially DIRS if these were insider trades. However, the sheer volume and format often appear in POS filings when a company is actively managing its treasury stock. I will lean towards POS as the primary fit for detailed transaction logs, but DIRS is a close secondary possibility. Given the lack of explicit context (like 'Form 4' or 'Insider Transaction'), and focusing on the transactional nature, POS is selected.
2021-03-09 Norwegian
Arctic Bioscience AS – Stabilization measures taken
Share Issue/Capital Change Classification · 99% confidence The document is titled "Arctic Bioscience AS – Stabilization notice" and details the offering size, price, stabilization period, and a table listing specific stabilization transactions with dates, quantities, and prices. This content directly relates to the management of share price following an offering, which falls under capital market activities. Among the provided definitions, 'Capital/Financing Update (CAP)' is the most appropriate category as stabilization activities are intrinsically linked to the financing and capital structure management following a share offering. It is not a general regulatory filing (RNS) because it is highly specific to a financing event, nor is it a transaction in own shares (POS) which typically refers to buybacks/repurchases outside of a stabilization context.
2021-03-09 Norwegian
Arctic Bioscience AS – Stabilization measures taken
Share Issue/Capital Change Classification · 99% confidence The document is a short announcement (1033 chars) referencing a previous stock exchange announcement regarding a Private Placement and the subsequent stabilization period. It explicitly states that the Stabilization Manager has taken measures 'set out in the attached notifications'. Because this document is short and serves primarily to announce that related stabilization actions/notifications are available elsewhere (likely attached or linked), it fits the criteria for a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Given the specific nature of announcing stabilization actions related to a financing event, RPA is a strong candidate, but since it's announcing the *results* of stabilization actions rather than the publication of a major report, RNS (General Regulatory Filing) is a safer fallback for specific market actions not covered by other codes like CAP or DIV. However, the core action is announcing the execution of stabilization measures following a financing event. Since 'Capital/Financing Update' (CAP) covers fundraising, and stabilization is directly tied to that, CAP might be considered, but the text focuses purely on the *stabilization* notification itself. Given the structure, it is a specific regulatory market action announcement. I will classify this as a general Regulatory Filing (RNS) as it is a specific market notice that doesn't fit the comprehensive report categories (10-K, IR) or the specific financing announcement (CAP) which usually details the terms, not just the stabilization execution notice.
2021-03-09 English
Arctic Bioscience signerer 3-årig avtale på 75 millioner kroner med Smerud Medical Research International for å gjennomføre klinisk studie på psoriasis
Regulatory Filings Classification · 99% confidence The document announces a significant business agreement between Arctic Bioscience and Smerud Medical Research International regarding a 3-year clinical study for a psoriasis drug candidate (HRO350), valued at 75 million NOK. This announcement details a major operational and strategic development concerning future product trials and financing context (recent listing). This type of announcement, detailing a major contract or strategic partnership that is not a standard periodic financial report (like 10-K or IR) or a simple management change, best fits the 'Capital/Financing Update' (CAP) if it involves significant funding/contractual commitment, or 'Regulatory Filings' (RNS) if it's a general material event disclosure. Given the focus on securing the execution of a major clinical trial, which is a key step in the capital deployment and development pipeline, it strongly relates to corporate financing/operational milestones. However, since it is a specific announcement of a major contract/collaboration rather than a direct capital raise or debt issuance, and it doesn't fit other specific categories like M&A (TAR) or Director Dealing (DIRS), it is most appropriately classified as a general material event disclosure. In the provided definitions, 'Regulatory Filings' (RNS) serves as the general regulatory announcement/fallback category for material events that don't fit elsewhere. It is not an Earnings Release (ER), Interim Report (IR), or a presentation (IP). It is a specific, material corporate announcement.
2021-03-03 Norwegian
Arctic Bioscience Signs 3-year Agreement Worth 75 Million NOK with Smerud Medical Research International to Conduct Clinical Study on Psoriasis
Regulatory Filings Classification · 94% confidence The document is a press release announcing a significant business agreement between Arctic Bioscience and Smerud Medical Research International to conduct a clinical study (Phase IIb) for a drug candidate (HRO350) treating psoriasis. This type of announcement, detailing strategic partnerships, clinical trial initiation, and associated contract values, is typically classified as a general corporate update or news release. It does not fit the specific definitions for financial reports (10-K, IR, ER), governance documents (CGR, DEF 14A), or shareholder actions (DIV, DVA). Since it is a specific corporate action announcement that doesn't fit the highly specialized categories like M&A (TAR) or Financing (CAP), the most appropriate general category for significant operational news that isn't a formal regulatory filing or financial report is Regulatory Filings (RNS), which serves as a broad category for miscellaneous corporate announcements not covered elsewhere, or potentially a general Investor Relations document. Given the nature of announcing a major clinical trial contract, RNS is the best fit as a catch-all for significant, non-standard corporate news releases.
2021-03-03 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.